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0735-6757/© 2016 The Authors. Published by Elsevier IncPatients taking direct oral anticoagulants (DOACs)who then need an emergency invasive procedure require spe-
cialized management strategies. Appropriate patient evaluation includes assessment of the current
anticoagulation state, including timing of the last dose. DOACs require particular coagulation assays to measure
anticoagulation levels accurately, although standard coagulation screening tests may provide qualitative guid-
ance. Specialty societies have endorsed general recommendations for patient management to promote hemosta-
sis in anticoagulated patients requiring surgery or other invasive procedures. These include general stopping
rules (such as ≥24 hours for low-risk procedures and ≥48 hours for high-risk surgerywith normal renal function)
for elective procedures. Bridging therapy when oral anticoagulant treatment is interrupted has recently been
questioned, depending on the clinical scenario. Novel agents for the reversal of DOAC-induced anticoagulation
have recently been developed. Idarucizumab, a humanized monoclonal antibody fragment that selectively
binds dabigatran, was recently approved for clinical use in patients with life-threatening or uncontrolled bleed-
ing, and for patients requiring emergency interventions. Idarucizumab can streamline the pre- and
periprocedural anticoagulation management of dabigatran-treated patients, as it provides fast, complete, and
sustainable reversibility. Andexanet alfa is an inactive, decoy factor Xa (FXa) molecule that binds FXa inhibitors,
and ciraparantag is a synthetic molecule designed to bind fractionated and unfractionated heparins, and each of
the currently approved DOACs. As clinical development of the additional anti-FXa-speciﬁc anticoagulant reversal
agents proceeds, the respective role of each in themanagement of emergency bleeding events and invasive pro-
cedures will be better deﬁned, and it is hoped they will make important contributions to patient care.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).When administered to reduce the risk of stroke in patients with
nonvalvular atrial ﬁbrillation (NVAF), the direct oral anticoagulants
(DOACs) are also associated with clinically important reductions in
the frequency of major bleeding, including life-threatening bleeding
events and, especially, intracranial bleeding, when compared with pa-
tients receiving warfarin [1-4]. Still, these events do occur, and thengelheim Pharmaceuticals, Inc.
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. This is an open access article underclinician may be faced with a need to reverse anticoagulation resulting
from a bleeding event or need for emergency surgery.
In such situations, the timing of the last DOAC dose allows estimation
of the time required for elimination from the plasma, and is therefore an
important consideration. Plasma concentrations of anticoagulants gener-
ally decrease to minimally effective levels within 3-5 half-lives, but the
exact timing may vary depending upon the agent and the patient’s over-
all clinical status. Recommendations based onpharmacokinetic andphar-
macodynamic studies have been made about the optimal time for
stopping DOAC-related anticoagulation [5-8]. In addition, a patient’s
renal function is an important consideration for elimination of most of
the DOACs, especially dabigatran, because lower creatinine clearance
(CrCl) rates are associatedwith elevated serum concentrations [9,10]. Po-
tential interactions with concomitant medications must also be consid-
ered, although for the most part, the DOACs are reported to have fewer
drug—drug interactions than do the vitamin K antagonists (VKAs) [5-8].
The management of patients who are treated with DOACs and later
require an emergency procedure due to trauma or other emergencies
continues to evolve with the development of experience and deﬁnitive
management strategies. This brief review will discuss topics known to
impact clinical care in DOAC-treated patients who require surgery or in-
vasive procedures, including assessing the current anticoagulationthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
15J.H. Levy / American Journal of Emergency Medicine 34 (2016) 14–18effect, their periprocedural management, current protocols for tempo-
rary discontinuations in DOAC therapy, and the utility of particular
DOAC reversal agents.
1. Measurement of Anticoagulation with the DOACs
Routine monitoring of anticoagulation is not generally recommend-
ed or required for patients treated with any of the approved DOACs.
However, in patients who are in need of an emergency surgical or inva-
sive procedure, an on-demand assessment of the current level of
anticoagulation effect is important [11,12]. It should be kept in mind
that key information to guide the interpretation of results from individ-
ual coagulation tests in these patients includes timing of the last dose of
the speciﬁc anticoagulant and the patient’s renal function [11].
There are a number of general considerations when assessing the
anticoagulation effects of individual DOACs, including the individual
drug in question, and the relevant coagulation assay that should be
used to assess its effects. The international normalized ratio (INR) was
developed to monitor anticoagulation associated with the VKAs, and is
not as reliable an assay for the assessment of the anticoagulant effects
of some factor Xa (FXa) inhibitors (apixaban) or dabigatran [13]. The
prothrombin time (PT)may provide a potential indication of the antico-
agulant effects of FXa inhibitors, but the assay is relatively insensitive
[13]. For example, the PT is not sufﬁciently sensitive to reliably measure
apixaban levels in therapeutic ranges [14,15]. Similar results have been
reported when the PT assay has been used to assess anticoagulation
with rivaroxaban, where PT results correlated poorly with rivaroxaban
concentrations [16]. In addition, results of this assay can vary depending
on the batch of individual reagents used to process the samples [13,16].
Specialized anti-FXa assays, which are distinct from those used for
low-molecular-weight heparin (LMWH), have been developed recently
and are recommended for quantitative measurements of rivaroxaban
and apixaban [17,18] and edoxaban [7]. However, for optimal perfor-
mance and accuracy, these assays will require individual calibration to
each speciﬁc drug [13,16].
The PT assay is generally not sensitive enough to reliably measure
clinically relevant dabigatran concentrations, but responses may be in-
creased with high levels of dabigatran [15]. A normal activated partial
thromboplastin time assay can be used as a screening tool to determine
a potential anticoagulation effect due to dabigatran, although this is not
the most sensitive assay available [13]. The thrombin time is a sensitive
assessment of dabigatran anticoagulation, but this assay can overesti-
mate dabigatran levels at high concentrations and is, therefore, most
useful as a qualitative tool [13]. The dilute thrombin time (dTT), as mea-
sured by the HEMOCLOT assay (HYPHEN BioMed, Neuville-sur-Oise,
France), best correlates with dabigatran plasma concentrations and is,
therefore, a more reliable measure of the anticoagulant effect of
dabigatran. However, this assay is not currently approved in the
United States [13,19]. In the European Union, measuring dTT with the
calibrated HEMOCLOT thrombin inhibitor assay is recommended as
the tool of choice for assessing the anticoagulation effect of dabigatran
[20]. Also in EU, the ecarin clotting time assay is often used in a fashionTable 1
Appropriateness of Assays for Monitoring the Activity of Direct Oral Anticoagulants [5-8,17,20,
Drug Quantitative Assays
(Provide an Estimate of Anticoagulant Drug Levels)
Direct FXa inhibitors (apixaban,
rivaroxaban, or edoxaban)
Speciﬁc, calibrated anti-FXa assays
Direct thrombin inhibitor (dabigatran) HEMOCLOT dilute thrombin assay,
ecarin clotting time
FXa = factor Xa.similar to the dTT to assess anticoagulant effects of dabigatran [21]. A
summary of the coagulation assays for each approved agent is provided
in Table 1[5-8,17,20,22].2. Periprocedural Management
A recent analysis from the Randomized Evaluation of Longterm
anticoagulation therapY (RE-LY) study (dabigatran vs VKA in patients
with NVAF) reported similar rates of perioperative bleeding and throm-
boembolism in warfarinand dabigatran-treated patients [23]. Similar
results have also been reported in studies of “real-world” populations
at high risk for thromboembolic and bleeding events for dabigatran
[24] and rivaroxaban [25] in general clinical practice.
Clinical decisions about the management of DOAC-treated patients
who require an invasive procedure should be based in part on the pa-
tient’s renal function, the length of time from last DOAC administration,
concomitantmedications that the patient is taking, and their overall risk
of procedural bleeding [26]. For example, in patients with moderate
renal impairment (CrCl 30-50 mL/min), medications such as the P-
glycoprotein (P-gp) inhibitors dronedarone or systemic ketoconazole
may increase exposure to dabigatran and potentially lead to hemostatic
dysfunction [5]. Similar concerns have been raised for co-administration
of FXa inhibitors and agents that are strong dual inhibitors of Cyto-
chrome P450 3A4 and P-gp (eg, ketoconazole, itraconazole, ritonavir,
and clarithromycin for apixaban) [6]; and diltiazem, verapamil,
dronedarone, and erythromycin for rivaroxaban [8]. Co-administration
of P-gp inhibitors such as amiodarone, cyclosporine, dronedarone,
erythromycin, ketoconazole, quinidine, and verapamil has been report-
ed to increase edoxaban exposure [7]. Concomitant use of rifampin, a P-
gp inducer, is also contraindicated in patients treatedwith edoxaban [7].
Recommendations for DOAC treatment interruption have beenmade
previously, especially for surgical patients, and are summarized below.
The European Society of Anaesthesiology and the French Working
Group on Perioperative Haemostasis (GIHP) recommend interruption
of DOAC therapy ~24 hours (2 or 3 half-lives) prior to a procedure that
carries a low bleeding risk, but 5 days prior to an interventionwith ame-
dium or high bleeding risk, dependent on the DOAC and factors such as
the patient’s renal function [27,28]. The European Heart Rhythm Associ-
ation’s guide to DOAC use suggests a general stopping rule of ≥24 hours
for low-risk procedures and ≥48 hours for high-risk surgery. However,
longer delays are suggested for patientswith a CrCl of b80mL/min taking
dabigatran and thosewith a CrCl of 15-30mL/minwho are administered
FXa inhibitors [26]. Other expert consensus documents recommend at
least a 24—48-hour discontinuation window for a particular DOAC
based on the speciﬁc agent, renal function, and high vs low risk of proce-
dural bleeding [29]. Speciﬁc guidance for discontinuation and bridging
for each approved agent are presented in Table 2[5-8,30-33]. It is impor-
tant to keep in mind that additional studies to assess standardized peri-
operative management protocols in DOAC-treated patients are ongoing,
and the results from these studies are expected to reﬁne our understand-
ing of this clinical challenge [29,34].22]
Qualitative Assays
(Indicate Presence or Absence of Drug Effect)
Not Recommended
Prothrombin time assay obtained in
seconds with sensitive reagents
Insensitive prothrombin time, activated
partial thromboplastin time,
dilute thrombin time or thrombin time
assays, or heparin-speciﬁc assays such
as the activated clotting time assay
Activated partial thromboplastin time,
thrombin time, activated clotting time assay
Chromogenic anti-FXa assays
Table 2
Discontinuation Guidance
Apixaban [6,30,31] Dabigatran [5,30,32] Edoxaban [7,30,31] Rivaroxaban [8,30,33]
Discontinuation
for surgery or
other
interventions
In cases where there is a low risk of
bleeding or when a potential bleeding
event would be in an easily controlled
noncritical location, apixaban should
be discontinued at least 24 h prior to
elective surgery or invasive
procedures.
In cases with a moderate or high risk
of unacceptable or clinically
signiﬁcant bleeding, apixaban should
be discontinued at least 48 h prior to
elective surgery or invasive
procedures.
Dabigatran should be discontinued
1-2 d (CrCl of ≥50 mL/min) or 3-5 d
(CrCl of b50 mL/min) in advance of
any invasive or surgical procedures.
For patients who require complete
hemostasis, such as those undergoing
major surgery, spinal puncture, or
placement of a spinal or epidural
catheter or port, longer
discontinuation times should be
considered.
Use of idarucizumab, a speciﬁc
dabigatran anticoagulation reversal
agent, should be considered in cases
where emergency surgery or urgent
procedures are needed.
Edoxaban should be discontinued at
least 24 h prior to invasive or surgical
procedures because of the risk of
bleeding.
If anticoagulation must be
discontinued to reduce the risk of
bleeding with surgical or other
procedures, rivaroxaban should be
stopped at least 24 h prior to the
procedure to reduce the risk of
bleeding.
Bridging Bridging anticoagulation is generally
not required during the 24-48 h after
stopping apixaban in advance of a
procedure.
If dabigatran is discontinued for other
than pathological bleeding or
completion of a course of therapy,
consider coverage with another
anticoagulant, and then restart
dabigatran as soon as medically
appropriate.
Administer a parenteral
anticoagulant and then switch to oral
edoxaban if oral medication cannot
be taken during or after surgical
intervention.
If oral medication cannot be taken
during or after surgical intervention,
consider administering a parenteral
anticoagulant.
Speciﬁc
reversal
agent
Speciﬁc FXa reversal agent
(andexanet alfa) is under accelerated
development and FDA review.
Ciraparantag, an agent to reverse the
anticoagulant effects of both LMWH
and UFH, and all 4 currently approved
DOACs is currently under
development.
Use the approved and available
speciﬁc reversal agent
(idarucizumab) in case of emergency
surgery or urgent procedures when
reversal of the anticoagulant effect of
dabigatran is needed.
Ciraparantag, an agent to reverse the
anticoagulant effects of both LMWH
and UFH, and all 4 currently approved
DOACs, is currently under
development.
Speciﬁc FXa reversal agent
(andexanet alfa) is under accelerated
development and FDA review.
Ciraparantag, an agent to reverse the
anticoagulant effects of both LMWH
and UFH, and all 4 currently approved
DOACs is currently under
development.
Speciﬁc FXa reversal agent
(andexanet alfa) is under accelerated
development and FDA review.
Ciraparantag, an agent to reverse the
anticoagulant effects of both LMWH
and UFH, and all 4 currently
approved DOACs is currently under
development.
Restarting
DOAC
As soon as adequate hemostasis has
been established after any surgical or
other procedure, apixaban should be
restarted.
Restart dabigatran as soon as
medically appropriate, or 24 h after
idarucizumab reversal.
Edoxaban can be restarted after the
surgical or other procedure as soon as
adequate hemostasis has been
established noting that the time to
onset of pharmacodynamic effect is
1-2 h.
Rivaroxaban should be re-started
after any invasive procedures as soon
as appropriate hemostasis is
established. It should be noted that
the time to onset of therapeutic
effect is brief.
Warnings Premature discontinuation of
apixaban increases the risk of
thrombotic events.
Epidural or spinal hematomas may
occur in patients treated with
apixaban who are receiving neuraxial
anesthesia or undergoing spinal
puncture.
An increased rate of stroke was
observed during the transition from
apixaban to warfarin in clinical trials
in atrial ﬁbrillation patients.
Premature discontinuation of any oral
anticoagulant, including dabigatran,
increases the risk of thrombotic
events.
Epidural or spinal hematomas may
occur in patients treated with
dabigatran who are receiving
neuraxial anesthesia or undergoing
spinal puncture.
Edoxaban has reduced efﬁcacy in
NVAF patients with a CrCl of N95
mL/min, and should not be used in
this population.
Premature discontinuation of
edoxaban increases the risk of
ischemic events.
Epidural or spinal hematomas may
occur in patients treated with
edoxaban who are receiving
neuraxial anesthesia or undergoing
spinal puncture.
Premature discontinuation of any
oral anticoagulant, including
rivaroxaban, increases the risk of
thrombotic events.
Epidural or spinal hematomas have
occurred in patients treated with
rivaroxaban who are receiving
neuraxial anesthesia or undergoing
spinal puncture.
CrCl= creatine clearance; DOAC=direct oral anticoagulant; FDA=U.S. Food and Drug Administration; FXa= factor Xa; LMWH= low-molecular-weight heparin; NVAF=nonvalvular
atrial ﬁbrillation; UFH = unfractionated heparin.
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Between Anticoagulants
Earlier guidelines for periproceduralmanagement of patients on oral
anticoagulation supported the discontinuation of oral anticoagulation
with warfarin and recommended the use of LMWH or unfractionated
heparin to bridge patients with atrial ﬁbrillation who are at elevated
risk for thromboembolic events [35,36]. More recently, the need for an-
ticoagulant bridging to allow invasive procedures to continue has been
called into question [37,38]. In fact, current guidelines from the
American Academy of Neurology state that bridging therapy with hep-
arin is probably associated with an increased bleeding risk when com-
pared with warfarin discontinuation [39]. These recommendations are
supported by a recent report from the BRIDGE Investigators, who state
that stoppingwarfarin (without bridgingwith LMWH), was noninferiorto bridging therapy when warfarin treatment was interrupted for an
elective operation or other elective invasive procedure [40].
Similar guidance is emerging for patients who are anticoagulated
with any of the currently approvedDOACs,where the limited data avail-
able suggest that bridging with another anticoagulant provides limited,
if any, beneﬁt to the patient. An example of this can be found in a recent
sub-analysis of data from the RE-LY study, where dabigatran-treated
patients who had treatment interruption for an elective procedure ex-
perienced more major bleeding events with bridging therapy than pa-
tients who did not receive bridging therapy, with no signiﬁcant effect
on arterial thromboembolism [41]. Anticoagulation with dabigatran
should begin as soon after the procedure as ismedically possible [5]. Re-
lated guidance is also provided by themanufacturer of apixaban [6] and
also does not recommend bridging therapy during DOAC treatment in-
terruptions. For patients on either edoxaban [7] or rivaroxaban [8],
17J.H. Levy / American Journal of Emergency Medicine 34 (2016) 14–18treatment should be stopped at least 24 hours prior to an invasive or
surgical procedure. A parenteral anticoagulant can be administered if
needed until an oral anticoagulant can be re-administered.
There is ongoing interest about the clinical need for bridging therapy
with heparin or other parenteral agents during DOAC treatment inter-
ruptions for invasive or surgical procedures. Randomized and con-
trolled clinical trials currently underway, such as the BRUISE
CONTROL-2, are expected to provide evidence-based clinical guidance
for the management of DOAC-treated patients who are facing invasive
or surgical procedures [42].
4. Reversal of DOAC-Induced Anticoagulation with Speciﬁc Agents
Several reversal agents to rapidly counter the anticoagulation effects
of DOACs are in development, and the respective roles for eachwill even-
tually bedeﬁned through formal studies and clinical experience. A speciﬁc
reversal agent for dabigatran, idarucizumab, is a humanized monoclonal
antibody that selectively binds dabigatran and reverses dabigatran-
induced anticoagulation. In the RE-VERSE AD (A Study of the RE-VERSal
Effects of Idarucizumab on Active Dabigatran) study, idarucizumab re-
versed the anticoagulant effects of dabigatran in patients with amajor
bleeding event, or who were in need of an urgent invasive procedure
(within 8 hours) [22,43]. Idarucizumab has recently been approved by
the U.S. Food and Drug Administration and the European Medicines
Agency for the reversal of dabigatran-related anticoagulation in cases
where emergency surgery or urgent procedures are required, or in cases
of life-threatening or uncontrolled bleeding [32].
Andexanet alfa is in advanced clinical trials as a speciﬁc reversal
agent of FXa inhibitors, including apixaban, edoxaban, and rivaroxaban,
and enoxaparin [44,45]. However, it should be noted that clinical trial
data have not yet been published where andexanet alfa was studied
for the reversal of anticoagulation in surgical patients, where emergen-
cy surgery or urgent procedures are required, or in cases of life-
threatening or uncontrolled bleeding. Andexanet alfa is a bioengineered
human FXa decoy protein that has been modiﬁed to delete the native
catalytic activity while retaining the high-afﬁnity binding of FXa inhibi-
tors within the enzymatic active site. By binding to circulating FXa in-
hibitors, andexanet alfa makes endogenous FXa available to contribute
to the coagulation cascade [45].
Another potential approach is ciraparantag (PER977), a small cationic
and water-soluble molecule that was designed to bind with high afﬁnity
to unfractionated heparin and LMWH by forming noncovalent hydrogen
bonds and strong chargeecharge interactions [30]. Ciraparantag binds in
a similar way to the oral FXa inhibitors, edoxaban, rivaroxaban, and
apixaban, and to the oral thrombin inhibitor dabigatran, potentially
achieving potent and rapid reversal of their anticoagulant effects [30].
As clinical experience with the reversal agents grows, the respective
role of each reversal agent in the management of emergency bleeding
events and surgical procedures will be better deﬁned over the next
few years, leading to important contributions in the care of patients
with NVAF and other thromboembolic challenges [46].
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